Flucox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucox

This section provides a foundational definition of the drug Flucox (Fluconazole), detailing its composition, classification, and general purpose without addressing specific clinical uses, dosage, or safety information. The entity Flucox is often associated with the active ingredient Fluconazole, a widely prescribed agent in the triazole class.

Quick Facts Description
Active ingredient Fluconazole
Form Capsule, Tablet, Intravenous Infusion Solution
Pharmacological class Triazole Antifungal Agent
General purpose To control and eliminate systemic fungal presence
Origin Synthetic derivative

What Type of Medicine is Flucox (Fluconazole)?

Flucox, defined by its active pharmaceutical ingredient Fluconazole, is a synthetic systemic antifungal drug, classifying it as an antimycotic agent. Fluconazole is a single-ingredient product belonging to the azole pharmacological class, specifically the triazole derivative subclass, a structure engineered for high oral bioavailability. This structural characteristic sets it apart from earlier azole antifungals, allowing it to be effectively absorbed into the bloodstream. The drug is characterized by its pharmacokinetics, which allows it to reach concentrations in various body tissues and fluids. This indicates that the medicine is designed to distribute itself to combat internal infections.


Forms, Administration, and General Purpose

Flucox is available in multiple pharmaceutical preparations, including solid capsules and tablets for oral administration, as well as an intravenous infusion solution. The general function of Flucox is to control and eliminate fungal presence by a fungistatic action accomplished through the disruption of fungal cell wall integrity.

This mechanism involves inhibiting the synthesis of ergosterol, a crucial fungal component. The availability of both oral and intravenous routes of administration allows for delivery via infusion in acute systemic situations and continuation with capsules or tablets during recovery phases. Fluconazole is a commonly utilized antifungal drug, reflecting its role against various pathogenic yeast species requiring systemic intervention.

Regulatory References

  1. Fluconazole: MedlinePlus Drug Information
  2. Diflucan - referral

What side effects are possible with Flucox?

Possible side effects and safety information

The regulatory documentation for Flucox (Fluconazole) outlines a safety profile classified by the frequency and organ system involved, derived from clinical use data. The most very common adverse reaction documented in official labels is headache.

Common reactions often involve the Gastrointestinal Disorders system, including nausea, vomiting, diarrhea, and abdominal pain. Other frequently listed effects include rash and transient elevations in liver enzymes (ALT, AST, Alkaline phosphatase).

Serious Adverse Reactions

The medicine is associated with documented rare but clinically significant adverse reactions. These include severe Hepatobiliary Disorders, such as hepatic failure and hepatic necrosis, which can occur regardless of dose or duration of therapy.

Regulatory documents also list rare Cardiovascular risks, specifically QT interval prolongation and Torsade de Pointes. Furthermore, potentially life-threatening Exfoliative Skin Disorders, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are classified as serious adverse reactions. Effects on the Blood and Lymphatic System, such as agranulocytosis and neutropenia, are also listed as rare events.

Population and Safety Context

Specific safety considerations are noted in official labeling. Patients with Renal Impairment may require adjustments in their prescribed amount. For immunocompromised patients, such as those with HIV/AIDS, regulatory data indicates a higher reported incidence of rash and severe skin reactions. Safety notes also advise that hepatic enzyme elevations are generally reversible upon discontinuation of therapy. The risk of QT prolongation means caution is advised in patients with potentially proarrhythmic conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes specific clinical signs associated with Flucox (Fluconazole) overdose. Documented presentations include severe central nervous system (CNS) effects, such as hallucination, paranoid behavior, and seizures.

Documented Serious Risks

A significant overdose carries the risk of serious systemic complications. The drug's high systemic exposure is associated with the potential for QT prolongation and the serious heart rhythm disorder Torsade de pointes.

Regulatory Mandates for Emergency Action

Regulators mandate immediate action for a suspected overdose. Seek immediate medical attention and contact emergency services if severe symptoms such as seizures, collapse, or difficulty breathing occur. Individuals are also directed to contact the poison control center.

Management of overdose is strictly symptomatic and supportive, as no specific antidote is known. The official procedure includes initiating supportive measures and considering gastric lavage if clinically indicated. Given that the drug is cleared primarily by renal excretion, hemodialysis is a documented procedure that can significantly reduce the plasma concentration of Flucox.

Therapeutic Uses of Flucox

What Flucox Treats: Main Uses and Benefits

Flucox (Fluconazole) is commonly used to address conditions presenting with systemic or localized discomfort. It is commonly used to address conditions marked by increased physiological stress such as candidemia (fungus in the bloodstream), disseminated systemic Candida infections, and Cryptococcal meningitis, along with conditions presenting with systemic or localized discomfort such as oropharyngeal thrush, esophageal candidiasis, and complicated vulvovaginal yeast infections.

The treatment plays a role in managing the systemic fungal presence. The medication is relevant when supportive symptom management is appropriate for patient groups where functional stability becomes affected, such as those with neutropenia or following transplantation.

Symptoms related to inflammatory or irritative states that may assist with management include symptoms related to physical discomfort and burning. Flucox contributes to easing the overall symptom load during periods of heightened symptoms, which assists with maintaining functional stability.

Quick Fact Focus Area: Supportive Benefit for Symptom
Systemic Imbalance Persistent fever and generalized malaise associated with acute episodes.
Functional Strain Painful swallowing (dysphagia) and localized burning discomfort.
Vulnerable Patient Groups Managing the risk associated with fungal threats.

Regulatory References

  1. NIH DailyMed Fluconazole Labeling

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults are generally eligible under standard conditions. Pediatric patients, including infants and neonates, are eligible for treatment of specific severe fungal infections. Older adults are eligible, but a formal assessment of kidney function is required.

Populations for whom use is contraindicated: Flucox is absolutely prohibited for patients with known hypersensitivity to fluconazole or other azole antifungal agents. It is also contraindicated for patients taking specific medicines known to prolong the QT interval and metabolized by the CYP3A4 system, such as cisapride or astemizole. Concomitant use with terfenadine is also prohibited at Flucox doses of 400 mg per day or higher.

Age-related eligibility rules: Use for the treatment of genital candidiasis in the pediatric population is not established. Treatment of Tinea Capitis is not recommended due to lack of established efficacy. Neonates have specific restricted dosing intervals based on age.

Condition-specific eligibility rules: Use requires caution and close monitoring in patients with pre-existing hepatic (liver) dysfunction or risk factors for cardiac arrhythmias. Patients with renal (kidney) impairment are eligible, but use is conditional, requiring dose adjustments based on creatinine clearance.

Pregnancy and lactation eligibility status: Use is not recommended during pregnancy unless the infection is severe or life-threatening. The label advises women of childbearing potential on prolonged therapy to use effective contraception. A single, low dose may be used while breastfeeding; however, repeated or high-dose use is not recommended.

What should I know about interactions with other medicines?

Flucox (Fluconazole) is formally documented to interact with a significant number of medicinal products, primarily by inhibiting specific hepatic cytochrome P450 (CYP) enzymes, which increases the systemic exposure of the co-administered drug.

Contraindicated Combinations

Co-administration with the following medicines is formally contraindicated in regulatory labeling due to the risk of cardiac toxicity (e.g., QTc prolongation and Torsades de Pointes):

Classification Specific Medicines Prohibited
Cardiac Risk Agents Astemizole, Cisapride, Pimozide, Quinidine, Erythromycin, and Terfenadine (at higher Fluconazole doses).

Documented Interaction Patterns

Flucox is classified as a potent inhibitor of CYP2C9 and CYP2C19 and a moderate inhibitor of CYP3A4. This pharmacokinetic mechanism can increase the plasma concentrations of medicines metabolized by these enzymes, including Warfarin, Statins (such as Simvastatin, Atorvastatin), Immunosuppressants (e.g., Cyclosporine, Tacrolimus), and Phenytoin. For instance, co-administration with Warfarin is documented to increase prothrombin time, which is an explicit pharmacodynamic risk.

Regulatory information notes that the enzyme inhibitory effect can persist for approximately four to five days following discontinuation of Flucox. Furthermore, the absorption of Flucox is officially unaffected by food; however, concomitant use with alcohol is documented as increasing the potential for liver damage.

Mechanism of Action

Targeted Inhibition of Fungal Sterol Synthesis

Flucox exerts its effect by acting within domains involving enzyme-mediated signaling and metabolic disruption unique to the pathogen. The drug selectively inhibits lanosterol 14-alpha-demethylase (CYP51), a vital fungal enzyme. This targeted mechanism influences the fungal processes driven by this distinct signaling pattern. The inhibition stops the conversion of lanosterol into ergosterol, the key structural molecule of the fungal cell membrane.

Disruption of Fungal Cell Membrane Integrity

This mechanism modifies early molecular steps that shape cellular physiological outcomes. By halting ergosterol production, the cascade leads to the depletion of essential membrane components and the simultaneous accumulation of toxic 14alpha-methyl sterols within the fungal cell membrane. The resulting physiological effect is the compromise of cell membrane integrity, which constrains the pathogen's ability to proliferate.

Constrained Fungal Growth (Fungistasis)

The drug engages mechanisms that influence feedback regulation within the pathway, leading to defined physiological changes that contribute to the mechanism's intended consequence. The cellular damage caused by the defective, leaky membrane and the presence of toxic sterols arrests the fungal pathogen's ability to grow and replicate. This process induces fungistasis by exerting pressure on the targeted pathways, resulting in a reduction in fungal cell proliferation.

Dosage and Administration Information

How to Use Flucox (Fluconazole)

The usage of Flucox is standardized concerning administration route, dosage patterns, and scheduling. The medicine is available in forms for both oral administration (capsules, tablets, and suspension) and intravenous (IV) infusion. Due to its high oral bioavailability, the prescribed dose is the same regardless of whether the oral or IV route is employed.

Treatment regimens typically commence with a loading dose on Day 1, which is generally double the subsequent maintenance dose, a pattern designed to rapidly achieve effective concentration levels. The maintenance dose is usually administered once daily. For example, in systemic infections, the maintenance dose commonly ranges from 200 mg to 400 mg daily, while acute vaginal candidiasis is treated with a 150 mg single oral dose.

Administration Conditions and Adjustments

Flucox may be taken with or without food. When administered intravenously, the solution must be infused at a maximum rate of 200 mg/hour.

The duration of therapy is dependent on the condition being addressed, ranging from a single dose to extended maintenance regimens, such as the long-term suppressive use required for certain fungal infections. Specific dosing modifications are mandatory for certain populations:

Population Group Official Dosing Adjustment (Excluding Single Doses)
Renal Impairment Dose reduction of 50% when creatinine clearance (CrCl) is leq 50 mL/min.
Hemodialysis Patients Full dose should be administered after each dialysis session.
Pediatric Patients Dosing is based on body weight (mg/kg) and must not exceed the maximum adult dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flucox (Fluconazole)

This overview summarizes the available research regarding the clinical evaluation of Fluconazole, detailing what types of studies have been conducted and what the research has explored, without offering clinical advice or interpretation. Findings described here reflect patterns observed in study populations according to authoritative scientific sources.


Evidence for Acute and Systemic Infections

Research exploring the use of Flucox in treating severe internal infections, such as when the fungus is present in the bloodstream (candidemia), is based primarily on Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies monitored outcomes related to systemic or functional imbalance, including measurements of microbiological measurements and all-cause mortality across defined time intervals.

Data show patterns related to microbiological measurements in susceptible strains; research describes that Fluconazole was studied for a transition (step-down) phase after initial treatment with another agent in some critically ill settings.

Evidence for Esophageal and Mucosal Candidiasis

The evidence base for infections of the mouth and throat, such as esophageal candidiasis and oropharyngeal thrush, relies on short-term RCTs. These trials were used in research exploring how symptoms change over time, including patient-reported outcomes describing perceived discomfort, such as painful swallowing (dysphagia), and findings related to microbiological eradication. Research typically describes outcomes over observation periods of 14 to 21 days following the start of the study drug.

Evidence for Maintenance and Prophylactic Use

For Cryptococcal meningitis, research focused on immunocompromised adults who had already completed the acute phase of intensive initial therapy. Studies monitored outcomes such as the prevention of relapse/recurrence and the sterility of the cerebrospinal fluid (CSF). The evidence indicates that Flucox was observed in trials specifically for the consolidation and secondary prophylaxis phases.

Flucox was evaluated in prophylaxis trials to reduce the risk of invasive fungal infection (IFI) in certain high-risk populations. Studies examined outcomes related to fungal infection rates and overall mortality in specific groups, such as very low birth weight infants and patients undergoing Hematopoietic Cell Transplant (HCT).

What Research Gaps and Uncertainties Remain

One of the main research limitation frames noted is the rising prevalence of specific Candida species (such as C. glabrata and C. krusei) that may be inherently less susceptible to Fluconazole. This means that evidence quality varies across studies based on the local distribution of fungal species. Additionally, the research on long-term outcomes and the potential for long-term effects are not fully established, particularly concerning the ecological shift toward less-susceptible fungal strains.

Frequently Asked Questions (FAQ)

Common questions about Flucox (FAQ)


Q: How quickly can a person generally expect Flucox to start working?

According to official drug documents, the highest concentration of the medicine in the bloodstream is usually reached between 1 and 2 hours after it is taken. For infections treated with a single dose, official documents indicate that symptomatic relief may begin to be perceived within the first 24 hours. When the medicine is taken daily, a consistent level in the body, known as steady-state concentration, is generally achieved within 5 to 10 days of starting treatment.


Q: Is Flucox the same type of medicine as [similar drug name]?

Flucox contains the active ingredient fluconazole, which belongs to a group of medicines called triazole antifungal agents. While it shares the same broad classification as other azole-type antifungals, it is a distinct chemical compound. Official sources classify Flucox as a synthetic systemic antifungal drug with its own specific mechanism and chemical structure.


Q: Can Flucox be affected by changes in body weight?

Official prescribing information confirms that the dose for children is calculated based on their body weight in milligrams per kilogram ( mg/kg). While standard adult doses are often fixed, regulatory-related research indicates that for certain patient groups, body weight may be considered as a factor in determining concentrations.


Q: What are the symptoms of taking too much Flucox?

In cases of excessive intake, official regulatory documents have reported specific effects such as hallucinations and paranoid behavior. The management of such events usually involves supportive measures, as described in clinical resources.


Q: Is Flucox the type of medicine that needs to build up in the system?

Yes, official dosing strategies are designed to ensure the medicine reaches an effective level quickly. This is often achieved by prescribing an initial loading dose, which is typically double the amount of the subsequent daily dose. This method aims to rapidly achieve steady-state concentrations (consistent levels in the body) within the first 48 hours.


Q: What is the usual recommended length of treatment with Flucox?

The official duration of use is highly dependent on the type and location of the fungal infection being treated. It can range from a single oral dose for acute, non-systemic infections to treatment lasting several weeks for others. For certain high-risk recurring infections, long-term suppressive treatment may be officially prescribed for six months or more.


Q: Why are there different brand names for medicines containing Flucox?

Flucox is a brand name used by a manufacturer for a product containing the active ingredient fluconazole. Once the original patent for a drug expires, other manufacturers may produce the same active ingredient and market it under their own brand names. Official regulatory lists contain both brand names and the generic name, fluconazole.


Q: Is it possible to take Flucox with herbal supplements?

Official medical information generally notes that interactions between prescription medicines like Flucox and herbal supplements are not routinely researched or documented. It is officially advised that all patients inform their health care provider about any medicines, including any herbal remedies, vitamins, or supplements, they may be currently taking.


Q: Are there any known issues with drinking coffee while taking Flucox?

Flucox has the potential to slow down how quickly the body processes and clears caffeine from the system. Some authoritative sources indicate that this effect may lead to increased concentrations of caffeine in the body. This could result in heightened side effects associated with caffeine, such as feeling jittery or having a fast heartbeat.


Q: What happens if a dose of Flucox is forgotten or missed?

Authoritative patient information generally describes the guidance as taking the forgotten dose when remembered, unless it is close to the next scheduled dose, in which case the missed dose is typically skipped. Taking extra medicine is not indicated to compensate for a missed dose.


Q: Has Flucox been studied in children or adolescents?

Yes, official regulatory documents confirm that Flucox has been formally studied in the pediatric population, including premature and full-term infants. The data gathered from these clinical studies are used to determine the appropriate dosing schedules and guidelines for its use in children and adolescents for the treatment and prevention of certain fungal infections.


Q: Is Flucox considered a long-term treatment option?

Flucox is officially indicated for long-term suppressive use (secondary prophylaxis) for specific medical conditions. Therefore, it is officially classified as an agent that can be used long-term under specific circumstances, such as preventing the recurrence of certain severe infections in immunocompromised patients.


Q: What are the official sources of information about Flucox?

The authoritative information for this medicine comes from sources like the FDA-approved Prescribing Information (also known as the professional label) and the Patient Information Leaflet (PIL), or Consumer Medicine Information (CMI). Other resources include general information found on government health websites like the NIH's MedlinePlus.


Q: Is it normal to feel a mild headache when starting Flucox?

According to official regulatory documentation, headache is listed as a very common adverse reaction. This means it is the side effect most frequently reported by patients using the medicine. Therefore, experiencing a mild headache when starting the treatment aligns with the published safety profile.


Q: Are there any known allergies to the non-active ingredients in Flucox?

Official product information advises that the medicine should not be used if a patient has a known sensitivity or allergy to fluconazole, to other related azole compounds, or to any of the excipients (non-active ingredients) listed in the medicine’s composition. These inactive ingredients are always listed in the official packaging leaflet.


Q: Does Flucox have an expiration date, and is it important to follow it?

All forms of Flucox are manufactured with a defined expiration date printed on the packaging, which must be followed. Furthermore, the liquid oral suspension form has a limited stability after it is mixed and is specified to be discarded after 14 days.


Q: Is it safe to take Flucox if I have another chronic health condition?

Official labels advise that use requires caution and close monitoring for patients with pre-existing conditions like hepatic (liver) dysfunction or risk factors for cardiac arrhythmias. The medicine’s use requires that a health care provider review all existing chronic conditions and treatments.


Q: Are there official registry studies or long-term safety data for Flucox?

While many studies exist on short- and medium-term use, the official research overview notes that the evidence regarding long-term outcomes and potential for long-term effects is not fully established. Safety information continues to be gathered through post-market surveillance and adverse event reporting systems, which constantly contribute to the medicine's safety profile.


Q: Does Flucox have any warnings related to sun exposure?

Official regulatory warnings advise that Flucox has been associated with reports of severe photosensitivity reactions. This means that the skin may become unusually sensitive to light. Patients may be advised to limit their exposure to direct sunlight or artificial UV light while they are taking this medicine.


Q: What are the official patient information leaflet for Flucox?

The official document containing consumer-level details about the medicine is called the Patient Information Leaflet (PIL) in many regions, or the Consumer Medicine Information (CMI) in others. This document is written for the user and is based on the full, regulatory-approved professional label.


Q: How are the side effects of Flucox typically managed?

Official guidance indicates that common side effects may be addressed by general supportive measures such as rest or fluid intake. However, any serious or severe side effects, as noted in the official warnings, require reporting and medical attention.


Q: Is there a link between Flucox and changes in blood pressure?

Flucox is not directly listed as a cause of blood pressure changes in official documents. However, the medicine is known to interact with certain other drugs that are used to manage high blood pressure. Therefore, if a patient is taking both medicines, the blood pressure may need to be monitored more frequently.


Q: Do health authorities issue a list of high-risk interactions for Flucox?

Yes. Health authorities explicitly list a number of medicine combinations that are formally contraindicated, meaning they are absolutely prohibited. These are generally considered the highest-risk interactions, primarily due to the potential for serious cardiac toxicity, and must be avoided.


Q: Is Flucox a common medicine, or is it considered a specialist prescription?

Flucox (fluconazole) is officially described as one of the most commonly prescribed antifungal drugs globally. It is utilized for both common and specialized systemic uses.

How should Flucox be stored and disposed of?

Storage and Disposal Conditions for Flucox (Fluconazole)

The storage and handling of Fluconazole must adhere strictly to regulatory labeling to maintain product stability.

Storage Requirements

Detail Condition
Temperature Tablets and capsules must be stored at controlled room temperature, generally below 30 C (86 F).
Protection The medicine must be kept out of the sight and reach of children and remain in its original container.
Handling Liquid forms (oral suspension and intravenous solution) must be protected from freezing.

Stability and Disposal

The reconstituted oral suspension has a limited shelf-life and must be discarded after 14 days (2 weeks).

Do not dispose of unused or expired Fluconazole via wastewater or household trash. The product must be disposed of according to local pharmaceutical waste regulations (e.g., drug take-back programs).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucox found in:

A-Z Index: